Your browser doesn't support javascript.
loading
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer.
Williamson, Casey W; Kotha, Nikhil V; Zou, Jingjing; Brown, Derek; Scanderbeg, Daniel; Rash, Dominique; Einck, John; Yashar, Catheryn; Mell, Loren K; Mayadev, Jyoti.
Afiliação
  • Williamson CW; Department of Radiation Medicine, Oregon Health & Science University, Portland, OR.
  • Kotha NV; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA.
  • Zou J; Herbert Wertheim School of Public Health and Human Longevity Science, University of California at San Diego, La Jolla, CA.
  • Brown D; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA.
  • Scanderbeg D; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA.
  • Rash D; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA.
  • Einck J; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA.
  • Yashar C; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA.
  • Mell LK; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA.
  • Mayadev J; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA. Electronic address: jmayadev@ucsd.edu.
Brachytherapy ; 22(3): 317-324, 2023.
Article em En | MEDLINE | ID: mdl-36631374
PURPOSE: To estimate local control, survival, and toxicity associated with a 3-fraction (3F) image-guided brachytherapy (IGBT) regimen compared to longer fraction (LF) for cervical cancer. METHODS: 150 patients treated between 2015-2020 with 3F (24Gy in 3 fractions) or LF (28...30 Gy in 4-5 fractions) were reviewed. The primary outcome was 2-year local failure. We compared overall survival (OS), disease-free survival (DFS), hospitalizations, and toxicity. RESULTS: There were 32 patients in the 3F group and 118 in the LF group, with a median follow up of 22 months. The 3F had worse performance status (p = 0.01) but otherwise similar characteristics. The 2-year local failure rate was 3.6% (95% CI 0%, 10.6%) for 3F, and 7.5% (95% CI 2.4%, 12.6%) for LF. The univariable hazard ratio (HR) for local failure for 3F was 0.43 (0.05, 3.43; p = 0.43). Moreover, 2 of 32 (6.3%) 3F patients experienced Grade ...3 toxicity compared to 7 of 118 (5.9%) LF patients (p = 1.0), with no difference in hospitalization within 2 years (p = 0.66) and no treatment-related deaths. CONCLUSIONS: Local control was excellent, with long term survival and toxicity similar between the groups. These findings support consideration of 3F.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Braquiterapia / Neoplasias do Colo do Útero Tipo de estudo: Guideline Limite: Female / Humans Idioma: En Revista: Brachytherapy Assunto da revista: RADIOTERAPIA Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Braquiterapia / Neoplasias do Colo do Útero Tipo de estudo: Guideline Limite: Female / Humans Idioma: En Revista: Brachytherapy Assunto da revista: RADIOTERAPIA Ano de publicação: 2023 Tipo de documento: Article